Head to Head Survey: Bolt Biotherapeutics (NASDAQ:BOLT) & Abbott Laboratories (NYSE:ABT)

Bolt Biotherapeutics (NASDAQ:BOLT) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Bolt Biotherapeutics and Abbott Laboratories”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$9.78 million	2.02	-$69.20 million	($1.71)	-0.30
Abbott Laboratories	$41.22 billion	4.75	$5.72 billion	$3.29	34.34

Abbott Laboratories has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Dividends

Bolt Biotherapeutics pays an annual dividend of $0.36 per share and has a dividend yield of 69.9%. Abbott Laboratories pays an annual dividend of $2.36 per share and has a dividend yield of 2.1%. Bolt Biotherapeutics pays out -21.1% of its earnings in the form of a dividend. Abbott Laboratories pays out 71.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bolt Biotherapeutics is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Bolt Biotherapeutics and Abbott Laboratories, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	0	5	0	0	2.00
Abbott Laboratories	0	4	11	0	2.73

Bolt Biotherapeutics presently has a consensus price target of $3.50, indicating a potential upside of 579.61%. Abbott Laboratories has a consensus price target of $131.57, indicating a potential upside of 16.47%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Abbott Laboratories.

Profitability

This table compares Bolt Biotherapeutics and Abbott Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-665.56%	-69.46%	-48.55%
Abbott Laboratories	13.99%	20.18%	10.84%

Volatility and Risk

Bolt Biotherapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Bolt Biotherapeutics on 10 of the 16 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.